GeneTether Therapeutics Inc.
CCSE:GTTXShare Statistics
As of September 30, 2024, GeneTether Therapeutics Inc. has 38.74M shares outstanding.
| Shares Outstanding | 38.74M |
Valuation Ratios
These figures are as of September 30, 2024.
| PB Ratio | -0.92 |
| P/TBV Ratio | 0.44 |
| P/FCF Ratio | -1.09 |
| P/OCF Ratio | -1.09 |
Financial Position
As of September 30, 2024, GeneTether Therapeutics Inc. maintains a current ratio of 34.52, meaning it holds 34.5x the short-term assets needed to cover near-term liabilities.
| Current Ratio | 34.52 |
| Quick Ratio | 34.52 |
Financial Efficiency
These figures cover the twelve months ended September 30, 2024. Return on assets (ROA) is negative at -56.45, reflecting losses generated across the asset base.
| Return on Assets (ROA) | -56.45 |
Dividends & Yields
These figures cover the twelve months ended September 30, 2024. Free cash flow yield is negative at -91.54: the business is consuming cash rather than generating it, so any dividend is not covered by free cash flow.
| FCF Yield | -91.54 |
Scores
As of September 30, 2024, GeneTether Therapeutics Inc. has an Altman Z-Score of 1.06, below the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.
| Altman Z-Score | 1.06 |